Company intelligence / Profile preview

Cayuga Biotech

Basking Ridge, New Jersey, United Statescayugabiotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Preclinical data shows their polyP-SNP (silica nanoparticle) complex generated thrombin 12 times faster than control, resulting in faster clotting with low potential for off-target thromboembolism. The therapy demonstrated ability to overcome conditions known as the "lethal triad"—hemodilution, acidemia, and hypothermia—which are associated with poor survival after injury with hemorrhage[6].

Therapeutic areas: Hematology
Modalities: Small molecule drugsChemical drugsBiomimetic polyphosphate-based therapies
Industry: Biotech

Drug pipeline

3 assets

CAY001

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cayuga Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cayuga Biotech.

Explore the full profile